Loading…
Liminatus Pharma, Inc. is projected to rise to $0.156 by 2027, a +36% move from its current price of $0.1144. LIMN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.1065 | $0.1144 | $0.1228 | 0.00% |
| Jul 14 | $0.1034 | $0.1144 | $0.1265 | 0.00% |
| Jul 15 | $0.1011 | $0.1144 | $0.1294 | 0.00% |
| Jul 16 | $0.0992 | $0.1144 | $0.1319 | 0.00% |
| Jul 17 | $0.0975 | $0.1144 | $0.1342 | 0.00% |
| Jul 18 | $0.0961 | $0.1144 | $0.1362 | 0.00% |
| Jul 19 | $0.0947 | $0.1144 | $0.1381 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.0947 | $0.1144 | $0.1381 | -0.01% |
| Week 2 | $0.0876 | $0.1144 | $0.1493 | -0.01% |
| Week 3 | $0.0825 | $0.1144 | $0.1586 | -0.02% |
| Week 4 | $0.0784 | $0.1144 | $0.1668 | -0.02% |
| Week 5 | $0.075 | $0.1144 | $0.1743 | -0.03% |
| Week 6 | $0.0721 | $0.1144 | $0.1815 | -0.03% |
| Week 7 | $0.0694 | $0.1144 | $0.1883 | -0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Liminatus Pharma, Inc. is a healthcare company described as a pre-clinical stage biopharmaceutical company that engages in the development of cancer therapies in the United States. Its efforts include developing IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
The company was founded in 2018 and is based in Cerritos, California.
The current price for LIMN is $0.1144 per share, and the company has a market cap of $7.07M. It ranks 5185 in market capitalization. These figures place the stock among smaller-cap healthcare names with ongoing clinical-stage programs.
A major floor 65.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 70.5% above — a clean break opens room to run.
A major ceiling 128.1% above — clearing it would confirm fresh momentum.
Key LIMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.1266 | Sell | $0.1218 | Sell |
| MA 10 | $0.1215 | Sell | $0.1221 | Sell |
| MA 20 | $0.1187 | Sell | $0.1265 | Sell |
| MA 50 | $0.1572 | Sell | $0.1626 | Sell |
| MA 100 | $0.1861 | Sell | $0.3623 | Sell |
| MA 200 | $0.6227 | Sell | $1.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.32 | Neutral |
| Stoch RSI (14) | 46.42 | Neutral |
| CCI (20) | -33.33 | Neutral |
| Williams %R (14) | -65.91 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 2.70 | Buy |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 34.09 | Neutral |
| TRIX (15) | -1.30 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 49.51 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.12 | Sell |
| ADX (14) | 19.36 | Neutral |
| ATR (14) | 0.01 | Info |
The sentiment is NEUTRAL with RSI(14) at 40. The 50-day simple moving average is $0.1572 and the 200-day simple moving average is $0.6227. The stock shows a defined support at $0.099 and a resistance at $0.195. The 30-day price range spans from $0.0715 to $0.183, and the annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.099 | $0.1144 | $0.1685 | 0% | Neutral | |
| $0.109 | $0.156 | $0.2422 | +36% | Bullish | |
| $0.1268 | $0.1958 | $0.3265 | +71% | Bullish | |
| $0.1054 | $0.1738 | $0.3062 | +52% | Bullish | |
| $0.0919 | $0.1608 | $0.2963 | +41% | Bullish | |
| $0.0856 | $0.1586 | $0.3038 | +39% | Bullish | |
| $0.0757 | $0.1482 | $0.2937 | +30% | Bullish | |
| $0.0766 | $0.1583 | $0.3233 | +38% | Bullish | |
| $0.0891 | $0.1943 | $0.4079 | +70% | Bullish | |
| $0.1089 | $0.242 | $0.5213 | +112% | Bullish | |
| $0.0984 | $0.2187 | $0.503 | +91% | Bullish | |
| $0.2069 | $0.4599 | $1.06 | +302% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.099 | $0.1144 | $0.1452 | +0.00% |
| August 2026 | $0.1004 | $0.1229 | $0.1575 | +7.45% |
| September 2026 | $0.0918 | $0.1143 | $0.1501 | -7.00% |
| October 2026 | $0.0844 | $0.1067 | $0.1429 | -6.68% |
| November 2026 | $0.09 | $0.1152 | $0.1569 | +7.97% |
| December 2026 | $0.0942 | $0.1219 | $0.1685 | +5.83% |
Click any year to see its month-by-month LIMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Liminatus Pharma, Inc.'s 2026 outlook centres on $0.1144, within a $0.099 to $0.1685 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LIMN could reach as high as $0.2422, with a base case around $0.156 and support toward $0.109 — roughly +36% from $0.1144. Momentum favours further upside here.
Expect LIMN to range from $0.1268 to $0.3265 through 2028. The $0.1958 average target implies a +71% move from current prices. That is up +25% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The LIMN price prediction for 2029 points to an average of $0.1738 (low $0.1054, high $0.3062) — a potential gain of +52% on today's $0.1144. Momentum favours further upside here.
In 2030, LIMN is projected to trade between $0.0919 and $0.2963, averaging $0.1608 — a potential gain of +41% from today's $0.1144. That is -7% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Liminatus Pharma, Inc.'s 2031 outlook centres on $0.1586, within a $0.0856 to $0.3038 range. That is -1% versus the projected 2030 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2032, LIMN could reach as high as $0.2937, with a base case around $0.1482 and support toward $0.0757 — roughly +30% from $0.1144. Buyers look set to stay in control over this stretch.
Expect LIMN to range from $0.0766 to $0.3233 through 2033. The $0.1583 average target implies a +38% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The LIMN price prediction for 2034 points to an average of $0.1943 (low $0.0891, high $0.4079) — a potential gain of +70% on today's $0.1144. Buyers look set to stay in control over this stretch.
In 2035, LIMN is projected to trade between $0.1089 and $0.5213, averaging $0.242 — a potential gain of +112% from today's $0.1144. That is up +25% on the projected 2034 average. Momentum favours further upside here.
Liminatus Pharma, Inc.'s 2040 outlook centres on $0.2187, within a $0.0984 to $0.503 range. That is -10% versus the projected 2035 average. That marks a +91% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LIMN could reach as high as $1.06, with a base case around $0.4599 and support toward $0.2069 — roughly +302% from $0.1144. Momentum favours further upside here.
Investing $1,000 in LIMN today (≈ 8,741.258741 LIMN) could be worth
$4,019.89
+$3,019.89 (+302%) by 2050 · US Dollar
Based on the average projected LIMN price of $0.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIMNwould be worth at today's price.
$1,000 invested in LIMN on Jul 10, 2025 (≈ 138.888893 LIMN) would be worth
$15.89
-$984.11 (-98.4%) today · 0.02× · US Dollar
Based on a LIMN entry price of $7.2 vs. today's $0.1144.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.143 | $800 | -20.0% |
| 1 month ago | $0.138 | $828.99 | -17.1% |
| 3 months ago | $0.188 | $608.51 | -39.1% |
| 6 months ago | $0.77 | $148.57 | -85.1% |
| 1 year ago | $7.2 | $15.89 | -98.4% |
| All time (1.2y) ago | $8.04 | $14.23 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIMN forecast.
Our base-case forecast reaches $0.23 around 2035.
Implied market cap at $0.23: $14.21M
The multi-year forecast shows a bullish trajectory beginning in 2027, with the average price rising from $0.156 in 2027 to $0.4599 in 2050. The modeled ROIs progress from 36.4% in 2027 to 302% in 2050. By year, the analysis projects 2028 average $0.1958 and max $0.3265 (71.1% ROI), 2029 average $0.1738 (51.9% ROI), 2030 average $0.1608 (40.6% ROI), 2031 average $0.1586 (38.6% ROI), 2032 average $0.1482 (29.6% ROI), 2033 average $0.1583 (38.4% ROI), 2034 average $0.1943 (69.8% ROI), and 2035 average $0.242 (111.6% ROI).
The long range also shows 2040 average $0.2187 (91.2% ROI) and 2050 average $0.4599 (302% ROI) with a max of $1.06. These figures point to a bullish outlook over time, though they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $0.0919; avg $0.1608; max $0.2963; ROI 40.6%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with ROIs listed, including 36.4% in 2027, 71.1% in 2028, 51.9% in 2029, and 302% in 2050. The 2026 figures are neutral with 0% ROI, so these are estimates and not guarantees.
Yes. The max forecast for 2050 is $1.06, which exceeds $1.00.
The 30-day range is $0.0715 to $0.183.
For 2050, min $0.2069; avg $0.4599; max $1.06; ROI 302%; sentiment BULLISH.
Liminatus Pharma, Inc. Community Discussion
0Share your Liminatus Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.